Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,316 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The cost of Alzheimer's disease in China and re-estimation of costs worldwide.
Jia J, Wei C, Chen S, Li F, Tang Y, Qin W, Zhao L, Jin H, Xu H, Wang F, Zhou A, Zuo X, Wu L, Han Y, Han Y, Huang L, Wang Q, Li D, Chu C, Shi L, Gong M, Du Y, Zhang J, Zhang J, Zhou C, Lv J, Lv Y, Xie H, Ji Y, Li F, Yu E, Luo B, Wang Y, Yang S, Qu Q, Guo Q, Liang F, Zhang J, Tan L, Shen L, Zhang K, Zhang J, Peng D, Tang M, Lv P, Fang B, Chu L, Jia L, Gauthier S. Jia J, et al. Among authors: luo b. Alzheimers Dement. 2018 Apr;14(4):483-491. doi: 10.1016/j.jalz.2017.12.006. Epub 2018 Feb 9. Alzheimers Dement. 2018. PMID: 29433981
Delayed help seeking behavior in dementia care: preliminary findings from the Clinical Pathway for Alzheimer's Disease in China (CPAD) study.
Zhao M, Lv X, Tuerxun M, He J, Luo B, Chen W, Wang K, Gu P, Kuang W, Zhou Y, Qu Q, He J, Zhang N, Feng Y, Wang Y, Yu X, Wang H; Clinical Pathway for Alzheimer’s Disease in China (CPAD) investigators. Zhao M, et al. Among authors: luo b. Int Psychogeriatr. 2016 Feb;28(2):211-9. doi: 10.1017/S1041610215000940. Epub 2015 Jul 3. Int Psychogeriatr. 2016. PMID: 26138923
Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial.
Xiao S, Wang T, Ma X, Qin Y, Li X, Zhao Z, Liu X, Wang X, Xie H, Jiang Q, Sun L, Luo B, Shang L, Chen W, Bai Y, Tang M, He M, Wu L, Ma Q, Hou D, He J. Xiao S, et al. Among authors: luo b. Age Ageing. 2017 Sep 1;46(5):767-773. doi: 10.1093/ageing/afx045. Age Ageing. 2017. PMID: 28419192 Clinical Trial.
Dementia in China: epidemiology, clinical management, and research advances.
Jia L, Quan M, Fu Y, Zhao T, Li Y, Wei C, Tang Y, Qin Q, Wang F, Qiao Y, Shi S, Wang YJ, Du Y, Zhang J, Zhang J, Luo B, Qu Q, Zhou C, Gauthier S, Jia J; Group for the Project of Dementia Situation in China. Jia L, et al. Among authors: luo b. Lancet Neurol. 2020 Jan;19(1):81-92. doi: 10.1016/S1474-4422(19)30290-X. Epub 2019 Sep 4. Lancet Neurol. 2020. PMID: 31494009 Review.
Consensus statement on the neurocognitive outcomes for early detection of mild cognitive impairment and Alzheimer dementia from the Chinese Neuropsychological Normative (CN-NORM) Project.
Wang H, Fan Z, Shi C, Xiong L, Zhang H, Li T, Sun Y, Guo Q, Tian Y, Qu Q, Zhang N, Cheng Z, Wu L, Wu D, Han Z, Tian J, Xie H, Tan S, Gao J, Luo B, Pan X, Peng G, Qin B, Tang Y, Wang K, Wang T, Zhang J, Zhao Q, Gauthier S, Yu X. Wang H, et al. Among authors: luo b. J Glob Health. 2019 Dec;9(2):020320. doi: 10.7189/jogh.09.020320. J Glob Health. 2019. PMID: 31893029 Free PMC article. Review. No abstract available.
Prediction of Alzheimer's disease using multi-variants from a Chinese genome-wide association study.
Jia L, Li F, Wei C, Zhu M, Qu Q, Qin W, Tang Y, Shen L, Wang Y, Shen L, Li H, Peng D, Tan L, Luo B, Guo Q, Tang M, Du Y, Zhang J, Zhang J, Lyu J, Li Y, Zhou A, Wang F, Chu C, Song H, Wu L, Zuo X, Han Y, Liang J, Wang Q, Jin H, Wang W, Lü Y, Li F, Zhou Y, Zhang W, Liao Z, Qiu Q, Li Y, Kong C, Li Y, Jiao H, Lu J, Jia J. Jia L, et al. Among authors: luo b. Brain. 2021 Apr 12;144(3):924-937. doi: 10.1093/brain/awaa364. Brain. 2021. PMID: 33188687 Free PMC article.
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia.
Xiao S, Chan P, Wang T, Hong Z, Wang S, Kuang W, He J, Pan X, Zhou Y, Ji Y, Wang L, Cheng Y, Peng Y, Ye Q, Wang X, Wu Y, Qu Q, Chen S, Li S, Chen W, Xu J, Peng D, Zhao Z, Li Y, Zhang J, Du Y, Chen W, Fan D, Yan Y, Liu X, Zhang W, Luo B, Wu W, Shen L, Liu C, Mao P, Wang Q, Zhao Q, Guo Q, Zhou Y, Li Y, Jiang L, Ren W, Ouyang Y, Wang Y, Liu S, Jia J, Zhang N, Liu Z, He R, Feng T, Lu W, Tang H, Gao P, Zhang Y, Chen L, Wang L, Yin Y, Xu Q, Xiao J, Cong L, Cheng X, Zhang H, Gao D, Xia M, Lian T, Peng G, Zhang X, Jiao B, Hu H, Chen X, Guan Y, Cui R, Huang Q, Xin X, Chen H, Ding Y, Zhang J, Feng T, Cantillon M, Chen K, Cummings JL, Ding J, Geng M, Zhang Z. Xiao S, et al. Among authors: luo b. Alzheimers Res Ther. 2021 Mar 17;13(1):62. doi: 10.1186/s13195-021-00795-7. Alzheimers Res Ther. 2021. PMID: 33731209 Free PMC article. Clinical Trial.
3,316 results